Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
NRG Oncology
National Cancer Institute (NCI)
BioNTech SE
Bristol-Myers Squibb
National Cancer Institute (NCI)
Second Affiliated Hospital of Nanchang University
Regeneron Pharmaceuticals
Daiichi Sankyo
Sutro Biopharma, Inc.
Ohio State University Comprehensive Cancer Center
Bio-Thera Solutions
West German Study Group
Seagen Inc.
Immutep S.A.S.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Semmelweis University
Leiden University Medical Center
Daehwa Pharmaceutical Co., Ltd.
1Globe Biomedical Co., Ltd.
RemeGen Co., Ltd.
Ain Shams University
Shanghai JMT-Bio Inc.
RenJi Hospital
Canadian Cancer Trials Group
The Netherlands Cancer Institute
National Cancer Centre, Singapore
Fudan University
Shanghai Zhongshan Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Peking University
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
Qilu Pharmaceutical Co., Ltd.
Canadian Cancer Trials Group
ChineseAMS
Velindre NHS Trust
Peregrine Pharmaceuticals
Peking University
Novartis
Transgene
Asan Medical Center
GBG Forschungs GmbH
University College, London
Merck Sharp & Dohme LLC
Chinese PLA General Hospital
Mateon Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hamamatsu University
Bristol-Myers Squibb